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28 April 2018Ninety-ﬁve percent of theWorld's populations have amean salt intake between 6 and 12 g,which ismuch lower
than the tolerated daily level of up to 55 g/d. In spite of this, the recommended upper level bymany health insti-
tutions is as low as 5.8 g/day. When reviewing the evidence for an upper level of 5.8 g/day, it becomes apparent
that neither the supporting studies selected by the health institutions, nor randomized controlled trials and pro-
spective observational studies disregarded by the health institutions, document that a salt intake below this 5.8 g,
has beneﬁcial health effects. Although there is an association between salt intake and blood pressure, both in ran-
domized controlled trials and in observational studies, this association is weak, especially in non-obese individ-
uals with normal blood pressure. Furthermore a salt intake below 5.8 g is associated with the activation of the
renin-angiotensin-aldosteron system, an increase in plasma lipids and increased mortality. A redesign of the
salt dietary guidelines, therefore, seems to be needed.
© 2018 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).Keywords:
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Fig. 1. Individual study systolic BP response to increasing changes in sodium urinary
excretion (as a measure of sodium intake) in otherwise healthy normotensive and
hypertensive individuals. Institute of Medicine7 used studies 13, 14 and 15 to estimate
the 5.8 g upper limit for salt intake *Burnier: J Hypertens 2000; 18:1657-64; *Fuchs:
BJMBR 1987;20:25-34; *Heer: AJPRP 2000; 27: 278:F585-95.
21N. Graudal, G. Jürgens / Progress in Cardiovascular Diseases 61 (2018) 20–26Introduction
Ninety-ﬁve percent of the World's populations have a mean salt in-
take between 6 and 12 g/d,1 theminimumrequired amount being about
0.5 g/d.2 Salt intake of up to about 55 g/d has been recorded.3 Random-
ized controlled trials (RCTs) of salt intake in the interval 0.5–40 g/d have
not reported deﬁciency or toxic symptoms.4 Intoxication has been de-
scribed after rapid intake of about 50 g or more over a few minutes.5
Salt is essential for life, as it contributes to the action potentials and
membrane potentials of cells and maintains extracellular volume and
blood pressure (BP).6 Centers in the brain regulate body salt, together
with the renin-aldosterone-angiotensin system (RAAS) and the
kidneys.6,7
Still, many health institutions agree that salt is as toxic as tobacco
and, therefore, consider salt to be a target for prevention.8,9 This position
is based on a belief that salt not only maintains BP, but increases BP as a
linear function of the ingested amount, leading to increased mortality.8
In recent years a signiﬁcant number of RCTs and population studies
have questioned the harmful effects of salt.4,10 Many health institutions
disagree and still support interventions to reduce salt intake in the gen-
eral population to below 5.8 g8,9,11 in parallel with attempts to reject the
outcomes of studies showing harmful effects of low salt intake.12 Repre-
sentatives from the American Heart Association (AHA) reviewed the
methodological quality of 26 population studies to analyze whether
methodological issues accounted for the lack of beneﬁcial effects of
low salt intake. They concluded that these studies, due to methodolog-
ical issues, were not suited to form the basis for salt guidelines, which
should instead be based on “the robust body of evidence linking Na
with elevated blood pressure and the few existing general population
trials of the effects of Na reduction on cardiovascular disease (CVD)”.12
However, as indicated in a meta-analysis of RCTs4 this evidence may
not be as robust as previously claimed.12 We therefore ﬁnd it pertinent
to present a collective critical review of the quality of the key health ev-
idence for salt reduction (SR) promoted by the health institutions in the
context of the existing evidence from RCTs and prospective population
studies.
Methods
We included RCTs and population studies aswell as studies based on
RCTs and population studies (meta-analyses and modeling studies) ini-
tiated or economically supported by the following health institutions
and organizations, which give high priority to salt reduction: Centers
for Disease Control and Prevention (CDC), National Institute of Health
(NIH), National Heart, Lung and Blood Institute (NHLBI), Institute of
Medicine (IOM, now National Academy of Medicine (NAM)),
American Heart Association (AHA), Food and Drug Association (FDA),
World Health Organization (WHO), and World Action on Salt and
Health (WASH). The study identiﬁcation was in part based on our
previous systematic searches of RCTs4 and population studies,10 and
reference lists from reports, studies and position papers published by
the mentioned institutions.
Salt: effect on BP
IOM (now NAM) report on dietary salt reference intake
The upper limit for salt intake of 5.8 g recommended by health insti-
tutions originates from an IOM report,8 which states, “most relevant to
determining an upper level are the three trials in which the lowest
level of dietary sodium intakewas close to the adequate intake (Johnson
et al., 2001; MacGregor et al., 1989; Sacks et al., 2001).” “In view of the
results from these three trials, the lowest-observed adverse-effect
level for dietary sodium is set at 2.3 g/day (5.8 g salt/day).” These 3
studies,13-15 which randomized individuals to 3–4 different doses of
salt (dose-response analyses), all showed a signiﬁcant proportionalincrease in BPwith increased salt intake both below and above a salt in-
take of 5.8 g, thus justifying the conclusion that salt intake should be
below 5.8 g. Fig. 1 shows all known dose-response studies published
at the time of the IOM evaluation. The 3 studies13-15 considered by
IOM were all studies of older individuals with hypertension (HTN)
and those with the steepest dose-response relationships. The HTN
studywith the lowest dose-response relationship16 and four normoten-
sive studies without dose-response relationships (Fig. 1)16,17 were not
included in the evaluation. This selective inclusion was further empha-
sized by the fact that high BP and age biased the three selected studies.
The ﬁrst study included older individuals with very high BP.13Mem-
bers of the WASH group performed the second study.14 This group has
published 10 studies in individuals with HTN showing a mean effect of
SR on systolic BP(SBP) of about 10mmHg, which is twice that reported
in all other RCTs of HTN (4.85 mm Hg) (Table 1). This indicates a sys-
tematic bias, which only partly depends on the high baseline BP of the
included populations. The chair of the 2005 IOM committee7 was co-
author of the third study.15 This study, the Dietary Approaches to Stop
Hypertension (DASH) study, is the most highlighted of the studies
used to justify SR.
The Dietary Approaches to Stop Hypertension (DASH) studies15,18
In the ﬁrst DASH study18 3 diets were compared, a control diet de-
pleted in potassium, calcium and magnesium to the 25% percentile of
the population in order “to ensure amarked contrast to the ideal dietary
patterns”. The ideal diet was rich in potassium, calcium, magnesium,
carbohydrate, protein and ﬁber and low in fat. The third diet was in be-
tween these two diets. At the time of the design of this study it waswell
known that potassium intake was inversely associated with BP.19,20
Thus the BP-reducing effect of the potassium rich fruit supplemented
DASH diet, identiﬁed in this study, may in part be ascribed to the
designed potassium depletion in the control group.
The experiences from the ﬁrst DASH trial18 were carried forward to
the subsequentDASH sodium trial,15 inwhich the intermediate dietwas
eliminated and the participants were randomized to the ideal and
Table 1
The effect of sodium reduction on systolic and diastolic blood pressure (SBP/DBP) in studies performed by researchers from theWorld Action on Salt and Health group.
Reference Mean age (years) Baseline SBP/DBP (mm Hg) Duration, (days) Sodium reduction (mmol) Effect SBP/DBP (mm Hg)
1) Lancet 1982;i:351 49 156/98 28 76 −10/−5
2) BMJ 1987;294: 531 52 150/97 30 100 −13/−9
3) J Hypertens 1988;6:613 52 157/101 5 97 −9/−5.6
4) Lancet 1989;II:1244 57 163/100 30 141 −16/−9
5) Hypertension 1991;17:798 54 147/91 30 91 −9/−3
6) J Hypertens 1994;12:809 49 144/100 5 296 −11.6/−5
7) J Hum Hypertens1996;10:523 46 151/96 7 293 −15.2/−3.7
8) Lancet 1997;350:850 67 162/90 30 81 −7.2/−3.2
9) Hypertension 2005;46:308 63 156/100 28 78 −8/−3
10) Hypertension 2009;54:482 50 147/91 42 55 −5/−3
Mean effect of study 1–10, SBP −10.21 [−12.75,−7.67]
Mean effect of study 1–10, DBP −4.30 [−5.68,−2.92]
Mean effect of all hypertensive studies except study 1–10, SBPa −4.85 [−5.80,−3.91]
Mean effect of all hypertensive studies except study 1–10, DBPa −2.67 [−3.27,−2.07]
a Data obtained from the data ﬁle of reference 23.
22 N. Graudal, G. Jürgens / Progress in Cardiovascular Diseases 61 (2018) 20–26control diets, respectively, and in addition crossed over to three differ-
ent salt intake diets. SR reduced SBP by 6.7 mmHg in the potassium de-
pleted control diet and by 3 mmHg in the ideal diet. A meta-analysis of
ﬁve studies identiﬁed among176 salt-reduction studies,4which in addi-
tion to allocation to a reduced salt diet also allocated participants to a
combination of sodium reduction and potassium supplementation,
shows a signiﬁcant BP difference between a low sodium/low potassium
diet versus a low sodium/high potassium diet (Fig. 2). This difference
corresponds to the differences observed in the DASH sodium trial, indi-
cating that the planned potassium depletion in the control group am-
pliﬁes the BP reduction induced by salt reduction. Furthermore, the
mean age, body mass index (BMI) and baseline BP of the included par-
ticipants were signiﬁcantly higher than the average American popula-
tion. This general bias is reﬂected in a supplementary publication of
the DASH trial, which shows that in younger individuals between 21
and 42 years, representing more than 50% of the American population,
the supplied low-sodium/high potassiumdiet has no effect on SBP com-
pared with the depleted low-sodium/low potassium diet.21 Due to the
design, interpretation and use of the DASH-sodium trial, it is a major
limitation that the data from this government-funded trial are not
publically available.22
WASH and WHO versus Cochrane: meta-analyses of the effect of reduced
dietary salt intake on BP
Cochrane has published two salt-reduction reviews by two different
author groups measuring exactly the same outcomes4,23; the justiﬁca-
tion being that the original review4 investigates acute effects of SR,
whereas the more recent review from 2004 by members of the WASHFig. 2.Meta-analysis of the effect of low sodium/high potassiumdiet vs. low sodium/lowpotassi
vs. low sodium control diet (low potassium) in the DASH study.15group23 investigates longer-term effects. However, in 2004 there was
no scientiﬁc justiﬁcation for this distinction and a later review of longi-
tudinal RCTs showed no differences in the effect of SR on BP between
week 1 and week 6.17 The WHO review24,25 includes almost the same
studies as theWASH review. Table 2 compares the original Cochrane re-
view, theWASH review and theWHO review. In general there were no
differences between the BP effects verifying that the distinction be-
tween acute and long-term studies is not justiﬁed. The marginally
higher effect in the analysis of normotensive studies in the WASH re-
view was due to the effect of the DASH study and 3 studies, which in-
cluded both normotensive individuals and those with HTN (Table 3).
After exclusion of these 4 studies the 8 remaining studies showed an
effect, which was almost identical with the Cochrane review and the
WHO review (Table 2).
CDC/FDA evidence for relation between reduced dietary salt intake and BP
Recently, the CDC and FDA released a proposal for voluntary guide-
lines to encourage food companies to steadily reduce sodium in proc-
essed and restaurant foods.11,26 The argument was “strong evidence,
including a recent analysis of more than 100 randomized clinical trials,
that sodium reduction reduces blood pressure in adults.” However,
this analysis27 was based on 65% HTN studies and 35% normotensive
studies. The meta-regression line with a slope of 3.8 mm Hg per
100mmol sodium (2.3 g sodium)was forced through zero andwas pri-
marily based on data adopted from the original Cochrane review.4 The
appropriate function with a constant reveals that the slope is only
2.27mmHg/100mmol (Fig. 3). The authors applied the no-constant lin-
earity from themixedmeta-regression analysis to both the HTN and theumdiet on systolic blood pressure and the effect of low sodium ideal diet (high potassium)
Table 2
Comparison of original Cochrane review (2003–2017), WASH group Cochrane review (2004–2013) and WHO review (2013): blood pressure.
Graudal et al. 2003/2011 (original)
Cochrane 2017 (4)
MacGregor et al. 2004 (WASH)
Cochrane 2013 (23)
Aburto et al.
WHO 2013 (25)
Hypertension Normal BP Hypertension Normal BP Hypertension Normal BP#
N (n) 86 (6001) 90(8833) 22 (990) 12(2240) 24 (2273) 7 (3067)
Median Age (range), years 51.6 29 50 50 – –
Median SBP/DBP, mm Hg 151/93 119/71 148/93 127/77 – –
Median duration, weeks 4 1 5 4 4 4
Usual sodium, mean, mmol 183 199 162 153 – –
Low sodium, mean, mmol 80 45 87 78 – –
Sodium reduction, mean, mmol 103 154 75 75 – –
Effect SBP/DBP −5.51/−2.88 −1.09−/0.03 −5.39/−2.82 −2.42/−1 −4.06/−2.26 −1.38/−0.58
Effect SBP/DBP (subgroup) (N,n) −1.31/−0.36 (59, 7125)a −1.63/−0.43 (8, 2113)b −1.38/−0.58 (7, 3067)
N: Number of studies; n: number of participants;
# 5 borderline studies were not included in the analysis.
a Studies with duration of at least 7 days.
b DASH study and studies of mixed hypertensive/normotensive individuals excluded.
23N. Graudal, G. Jürgens / Progress in Cardiovascular Diseases 61 (2018) 20–26normotensive individual studies and standardized the systolic BP effect
to 2.3 g (100 mmol). In contrast, a separate meta-regression analysis of
thenormotensive studies shows that neither the assumption of linearity
nor the cut point of zero is valid for the normotensive studies (Fig. 3).
Thus the CDC and FDA assumed dose-response relationship is not
valid for the 75% of the population with a normal BP.
CDC/NHLBI analysis of association between salt intake and BP inNHANES 2014
In themain article this recent analysis shows an association between
sodium intake and BP, which is stronger than found in previous popula-
tion studies (4.58/2.25mmHg/1gNa).28However, according toeTable 2
in their supplement, this effectwasmainly due to the adipose 50% of the
population with a BMI above 30. In the group of participants with a BMI
less than 30 the systolic BP effect was only 1.8 mm Hg/1 g Na. This is
similar to the effect found in theworldwide Prospective Urban Rural Ep-
idemiology (PURE) study (2.1 mmHg/1 g Na), in which the study pop-
ulation had a mean BMI of 26.29
Salt: effect on hormones and lipids
WASH and WHO versus Cochrane: meta-analyses of the effect of reduced
dietary salt intake on hormones and lipids
The effect of salt-reduction on renin, aldosterone, noradrenalin,
adrenalin, cholesterol and triglyceride has been analyzed in the three
previously mentioned meta-analyses.4,23,25 The results are presented
in Table 4. The original Cochrane review4 reduces salt-intake to aTable 3
Studies of participants with normal BP included in WASH Cochrane meta-analysis, 201323
Reference Baseline SBP/DBP
mm Hg
S
H
Puska, Lancet 1983;I:1-5. 132/82 1
Watt, BMJ 1985;291:1525-8 113/65 1
Mascioli, Hypertension 1991;17(S1):I21-6 131/84 1
TOHP I, JAMA 1992;267:1213-20 125/83 1
Cobiac, J Hypertens 1992;10:87-92 134/78 1
Ruppert, Hypertens 1993;11:743-9 113/72 2
Nestel, Hypertens 1993;11:1387-94 129/77 1
Schorr, J Hypertens 1996;14:131-5* 132/72
D12h**: 140/84
1
Cappucio, Lancet 1997;350:850-4* 149/84 1
TOHP II, Arch Intern Med 1997;157:657-67 128/86 1
DASH, NEJM 2001;344:3-10* 129/84 1
Melander, J Hypertens 2007;25:619-27* 136/78
D12h**: 141/90
1
*Excluded in sensitivity analysis; **12 h BP during daytime; HH: Parents high BP; LL: Parents lomean level below 5.0 g in accordance with the recommendations,
whereas the two small analyses of studies of at least 4 weeks
duration23,25 reduce salt intake down to, but not below, a mean level
of 5.0 g corresponding to the WHO recommendations, which are to re-
duce salt below 5.0 g/d.24 Thus, the level of salt intake, rather than the
duration of the exposure, determines the occurrence of side effects.
This has been veriﬁed in Yanomamo Indians on low-salt intake, who
have persistently elevated levels of renin and aldosterone in the
blood2; and in a cross-sectional study of individuals with normal BP
and hypertension.7 RAAS is activated by salt reduction in healthy and
sick individuals, butMcCarron suggested that in patientswith heart fail-
ure (HF) and renal disease, whose RAAS is activated by a compromised
renal perfusion, the activated RAAS might dictate a neural-driven in-
crease in salt intake in an attempt to increase renal perfusion and sup-
press plasma renin activity and angiotensin II and its pathologic
impact on the heart and vasculature.30 Under these circumstances a
high salt intake was suggested not to be causative, but more likely a
compensatory response mechanism, serving as a natural RAAS
inhibitor.30 That interpretation is consistent with recent studies of pa-
tients with HF and renal disease showing that a low salt diet was not as-
sociated with reduced morbidity or mortality.31,32
Salt: effect on health outcomes
RCTs relating salt intake to health outcomes
RCTs measuring health effects have been performed in individuals
with HTN and pre-HTN overweight individuals, but not in healthyodium intake, mmol
igh/low
SBP effect mm Hg DBP effect mm Hg
92/77 −1.5 (3.32) −2.1 (2.03)
30/68 (HH)−1.4 (0.74)
(LL)−0.5 (0.82)
1.2 (0.93)
1.4 (0.9)
79/109 −3.6 (0.9) −2.3 (0.8)
44/100 −1.7 (0.59) −0.9 (0.42)
48/79 −1.7 (2.14) 0.8 (1.01)
00/82 1.7 (2.39) 1 (1.64)
57/106 (F) −6 (4.9)
(M) −2(3.43)
−2 (3.31
−1 (2.65)
66/105 −7.2 (4.9) −2.9 (2.61)
67/91 −8.2 (3.07) −3.9 (1.65)
78/135 −1.2 (0.5) −0.7 (0.4)
41/64 −5.3 (0.77) −2.6 (0.5)
40/51 −4.6 (2.1) −2.8 (1.03)
w BP; F: Female; M: Male.
Fig. 3. Sodium reduction versusmean reduction of systolic blood pressure (MRSBP). Univariable analysis: Each circle shows theMRSBP outcome of one study comparing a reduced sodium
intake versus a usual sodium intake (closed circles: Normotensive studies; stippled circles: Hypertensive studies). The size of the circle corresponds to its inverse variance weight of the
MRSBP. Regression lines are shown for all studies with recommended method including a constant (y = −0.0227×−2.0374), the no-constant method (y = −0.0382×) and for
normotensive studies only (y =−0.0005×−1.988).
24 N. Graudal, G. Jürgens / Progress in Cardiovascular Diseases 61 (2018) 20–26individuals. Collectively they showed a non-signiﬁcant 24% reduction in
CVD events in the low-salt group (data incompletely recorded) and no
difference in all-cause mortality (data completely recorded).33 The
mean salt intake in the low-salt groups was 5.8 g or higher. Thus there
are no RCTs to show health effects of salt-intake below 5.8 g.
Modeling studies relating salt intake to health outcomes
Modeling studies establish a dose-response relationship between
salt intake and BP, which indirectly is used to translate salt reduction
to reduction in mortality by means of data from observational studies
linking BP tomortality. Onemodeling study34 used the linear regression
analysis based on data from the WASH meta-analysis (Table 3), data
from the DASH study15 (Fig. 1) and data from one of the WASH group
studies14 (Fig. 1) (study no. 4 in Table 1) to construct the dose-
response analysis. Another study27 used the data from the above de-
scribed meta-regression analysis of 103 RCTs of which 65% were HTN.
None of the modeling studies included side-effect data in the models,Table 4
Comparison of original Cochrane review (2003–2017), WASH group Cochrane review (2004–2
Graudal et al. 2003/2011 (original)
Cochrane 2017 (4)
N studies 16–88
Low sodium, mmol (Hy/No) 80/45
Effect renin SMD, (p) 1.22 (0.00001)
Effect aldosterone pg/ml (p) 98 (0.00001)
Effect noradrenaline pg/ml, (p) 64 (0.00001)
Effect adrenalin pg/ml, (p) 8 (0.03)
Effect cholesterol mg/ml, (p) 5.6 (0.0005)
Effect triglyceride mg/ml, (p) 7 (0.0006)
Hy Hypertensive; No: Normotensive.although side-effect data were available in the meta-analyses from
which the BP data were adopted. These models predicted thousands
to millions of saved lives by dietary salt reduction in contrast to real
data from cohort studies, which indicate that low salt intake is associat-
ed with increased mortality.
Cohort studies relating salt intake to health outcomes
Evidence fromWHO is based on ameta-analysis from 2009,35which
was updated in 2013.25 In the 2009 analysis the relative risk of higher
versus lower salt intake was investigated by comparing the event rate
in the two categories with a difference in average salt intake closest to
5.8 g/day. In the updated analysis25 the overall effect estimate was gen-
erated comparing the risk of each outcome in the lowest salt intake
group with the highest salt intake group. A third analysis used similar
methods.36 In several of the population studies the salt intake in the
lowest salt group was within the usual range of salt intake (6–12 g).
Thus, none of these three analyses provided data on the separate013) and WHO review (2013): hormones and lipids.
MacGregor et al. 2004 (WASH)
Cochrane 2013 (25)
Aburto et al.
WHO 2013 (27)
4–14 4–11
87/78 87/78
0.26 (0.00001) –
73 (0.00001) –
32 (0.01) 8.23 (NS)
6.7 (0.06) 6.90 (NS)
1.9 (NS) 0.02 (NS)
3.5 (NS) 0.04 (NS)
25N. Graudal, G. Jürgens / Progress in Cardiovascular Diseases 61 (2018) 20–26signiﬁcance of a low salt intake below 5.8 g. Thiswas done in an IOM re-
port, which concluded that outcomes of population studies were insuf-
ﬁcient to show whether low salt intake below 5.8 g had beneﬁcial or
harmful health effects.37 The ﬁrst essential meta-analysis to investigate
the separate effect of low salt intake indicated a U-shaped relationship
between salt intake andmortality, especially in study samples represen-
tative for the general population adjusted for multiple effect
modiﬁers.10 Previously, several individual population studies had iden-
tiﬁed this U-shape.31,38–40 Lately, the U-shape was again conﬁrmed in a
meta-analysis of four recent studies.41 A separate analysis of individuals
with HTN based on individual participant data conﬁrmed the U-shape,
but in individuals with normal BP only the low salt intake was associat-
ed with increased mortality, whereas a high salt intake up to 30 g per
day was not.41 Table 5 summarizes the results from the meta-
analyses. All analyses agree that high salt intake above the mean usual
intake is associated with increased mortality in populations of individ-
uals with and without HTN. The latest of the analyses indicate that
this effect only applies to those with HTN. Furthermore the analyses,
which separately investigated low salt intake, agreed that low salt in-
take was associated with increased mortality.10,41
AHA advisory on cohort studies relating salt intake to health outcomes
Representatives of AHA reviewed a series of limitations in the popu-
lation studies, which had the potential to alter the direction of the asso-
ciation between salt intake and health outcomes.12 Potential for
systematic error, for instance in the estimation of salt intake, was iden-
tiﬁed in most of the 26 reviewed population studies and speciﬁc sys-
tematic error was identiﬁed in 6. However, in order to reverse the
direction of the health outcome the systematic error should misclassify
speciﬁc groups and such systematic errors were not speciﬁcally identi-
ﬁed. Random error due to single estimation of the salt intake was also
potentially present in most studies. Multiple measurements could re-
duce this error and increase the precision of the estimation of the salt
intake,42 which should strengthen the direction of the outcome, but
not reverse the outcome, as veriﬁed in two recent studies.32,43 One
study based on multiple 24-h sodium excretions did not ﬁnd a signiﬁ-
cantly increased (or reduced) rate of CVD44 or all-cause mortality45 in
the low salt group. The authors explained this contrast to the meta-
analyses10,41 as being due to the multiple salt intake estimates used in
these analyses.44,45 However, as it is less likely that multiple measure-
ments reverse the direction of the outcome, the use of less precise
food frequency questionnaires or spot urines tomeasure the sodium in-
takewould probably have yielded similar results. Amore reasonable ex-
planation for the lack of U-shape may be that the investigated
individuals suffered from overweight and pre-hypertension or that
few individuals with few events were on a low salt diet, limiting the
power to detect associations in the interval below 5.8 g.
The possibility that sick individuals eat less salt could also explain in-
creased mortality associated with low salt intake (reverse causality).12Table 5
Meta-analyses of population studies: relative risk (RR) for all-cause mortality (ACM), car-
diovascular disease event (CVD) or stroke.
RR (low salt versus
usual salt)
RR (high salt versus
usual/low salt)
Reference Populations ACM CVD Stroke ACM CVD Stroke
Strazzulo35 All (RPS + IPS) – – – – 1.14 1.23a
WHO25 All (RPS + IPS) – – – 1.06 1.12 1.24a
Poggio36 All (RPS + IPS) – – – – 1.12a –
Graudal10 All (RPS + IPS) 1.10a 1.10a 0.96 1.16a 1.12a 1.18a
Graudal10 RPS 1.16⁎ 1.07 0.95 1.04 1.07 1.21a
Mente41 Normal BP 1.39a 1.28a – 1.00 0.90 –
Mente41 Hypertesion 1.39a 1.35a – 1.39a 1.26a –
RPS: Representative population samples; IPS: Ill population samples.
a Statistically signiﬁcant.We have not seen this hypothetical phenomenon veriﬁed in any
study. Conversely, the recently published analysis of NHANES 2014
shows that individuals with HTN, diabetes mellitus, CVD and chronic
kidney disease have salt intakes similar to healthy individuals. This
study also showed that individuals reporting to have intentionally de-
creased their salt intake had the same salt intake as those reporting to
have unchanged salt intake.46 Besides, most of the population studies
reported in the meta-analyses10,41 adjusted for confounders including
diseases. Finally, both of the large meta-analyses10,41 and the largest of
the population studies40 showed that elimination of sick study popula-
tions and sick individuals strengthened the association between low-
salt intake and mortality.
Conclusions
Various biases are prominent in studies supporting salt reduction,
such as selective evaluation of mainly salt sensitive HTN study
populations8,27,34 (Table 1) or salt sensitive overweight study
populations,15,28,44,45 or intentional deﬁnition of study inclusion criteria
to increase salt sensitivity of the group of participants being studied,
such as high baseline BP, overweight and reduction of potassium to sub-
normal levels in the control diet,15,44,45 and denial of potential low-salt
side-effects.25,27,34–36 The extraordinary associations of salt with BP and
health outcomes in these studies disappear in subgroup analyses
adjusting for these biases. This selective prioritization in the choice
and methods of evidence to support dietary guidelines, such as Dietary
Guidelines of America (DGA)9 has been criticized previously.47–50 Al-
though the latter50 mainly deals with fat and carbohydrate recommen-
dations, it does emphasize the paradox that DGA says that it “concurs”
with the IOM report, which states that the evidence is “inconsistent
and insufﬁcient to conclude that lowering sodium intakes below 2300
mg/day will have any effect on cardiovascular risk or overall
mortality”37 and yet DGA recommends that sodium intake “should be
less than 2300mg/day”.9 Recently, this distrust in the process for the es-
tablishment of DGA has been supported in the conclusion of a National
Academy of Medicine report: “Collectively, these ﬁndings and conclu-
sions compromise the integrity of the DGA and limit its ability to devel-
op a full body of evidence on a continuous basis over time. The process
to update the DGA should be comprehensively redesigned to allow it to
adapt to changes in needs, evidence, and strategic priorities”.51 Tempo-
rarily, these concerns have had no impact. DGA and other health institu-
tions maintain the idea that the majority of the World's populations
have a too high salt intake. This idea should be evaluated in the context
that this “high” salt intake (6–12 g) is in the low end of the tolerable in-
terval (0.5–55 g), just above the level associatedwith side effects and in-
creased mortality. A redesign of the salt DGA seems to be needed.
Conﬂict of interest
None.
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